Meeting Minutes: Drug Formulary Committee (DFC) - DRAFT

Date and Time: July 15, 2026: 9:15a.m. – 1:30 p.m. (Central Time)
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2370

Attendance

Members in attendance: Jacques Beasley; Mary Mescher Benbenek, PhD, APRN; Jeannine Conway, PharmD; Emily Jaeger, PharmD; Katherine Montag Schafer, PharmD; Emma Ryan, PharmD; Kelly Ruby, PharmD; Sheila Scheuer, PharmD; Romie Tinsay, MD; Jena Wirt, DO; Julie Wolfgram, DNP, FNP
Members absent: Sandra Widhalm Murphy, RPh
DHS staff present: Nathan Chomilo, MD; Chad Hope, PharmD; Dave Hoang, PharmD, MBA; Aaron Drake, RPh
Others in attendance: Naana Osei-Boateng, PharmD; Chloe Groomes, PharmD; Andrew Wherley, PharmD; Laura Pounders, PharmD

Report of the Chair

- Kelly Ruby presided over the meeting.

Approval of Minutes

- The DFC approved the minutes from the March 2026 meeting.

DHS Housekeeping

- Stuart Williams and Arthur Beisang are no longer members of the DFC. DHS thanked them for their service and dedication to the work of the DFC.
- In light of Stuart William's departure from the Committee, a new chair will need to be elected. This will be done at the next meeting of the DFC.

Old Business

- None

New Business:

Specialty Drugs for Continued PA

- The committee discussed Forzinity and recommended to DHS by a unanimous vote that Forzinity remain on PA with the following amendment to the proposed criteria:
    - Initial approval criteria, bullet point #2 be changed to read: "Diagnosis of Barth Syndrome confirmed by a pathogenic or likely pathogenic hemizygous variant in TAFFAZIN; OR a clinical phenotype supportive of Barth Syndrome and an abnormal monolysocardiolipin-to-cardiolipin ratio…"

- The committee discussed Itvisma and recommended to DHS by a unanimous vote that Itvisma remain on PA with the following amendments to the proposed criteria:
    - Initial approval criteria, bullet point #4, first sub bullet; be changed to: "Patient is treatment-naïve for any SMN-targeting agents for SMA (e.g., nusinersen [Spinraza], risdiplam [Evrysdi]) …" (delete 'AND is able to sit independently but has never had the ability to walk independently')
    - Initial approval criteria, bullet point #4, second sub bullet ii; be changed to: "Has up to 4 copies of the SMN2 gene…"
    - Initial approval criteria, bullet point #4, be changed to: "Patient is up to date with all vaccinations in accordance with current vaccination guidelines, prior to initiating therapy..." (delete '(including seasonal prophylaxis against respiratory syncytial virus [RSV])',

- The committee discussed Redemplo and recommended to DHS by a unanimous vote that Redemplo remain on PA with the following amendment to the proposed criteria:
    - Initial approval criteria, bullet point #, sub bullet iii be removed (deletion of "History of pancreatitis or unexplained recurrent abdominal pain" from the criteria)

- The committee discussed Voyxact and recommended to DHS by a unanimous vote that Voyxact remain on PA with the proposed criteria.

- The committee discussed Aqvesme and recommended to DHS by a unanimous vote that Aqvesme remain on PA with the following amendment to the proposed criteria:
    - Renewal criteria; bullet point #1 be changed to "Prescriber has reviewed any new Aqvesme drug interactions and will monitor patient status as appropriate…"

- The committee discussed Myqorzo and recommended to DHS by a majority vote that Myqorzo remain on PA with the proposed criteria.

- The committee discussed Veopoz and recommended to DHS by a unanimous vote that Veopoz remain on PA with the following amendments to the proposed criteria:
    - Removal of references to ACIP in the criteria

Preferred Drug List (PDL) Review

DISCUSSION ITEMS:

- The committee discussed the Antidepressants, Other therapeutic class and recommended the following to the department by a unanimous vote:
    - FETZIMA (ORAL), TRINTELLIX (ORAL) and VILAZODONE (ORAL) to be moved on the PDL to PREFERRED.
    - DESVENLAFAXINE ER (NO BRAND) (ORAL) and VIIBRYD (ORAL) to be moved on the PDL to NONPREFERRED.
    - EXXUA TAB ER (ORAL), EXXUA TAB ER TITRATION PK (ORAL) and RALDESY SOLUTION (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Antidepressants, SSRIs therapeutic class and recommended the following to the department by a unanimous vote:
    - ESCITALOPRAM CAPSULE (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Antimigraine Agents, Other therapeutic class and recommended the following to the department by a unanimous vote:
    - AJOVY AUTOINJECTOR 3-PK (SUBCUTANE.) to be added to the PDL as PREFERRED (simply clarifying that all presentations of Ajovy are preferred).
    - QULIPTA (ORAL) to be moved on the PDL to PREFERRED.
    - BREKIYA AUTOINJECTOR (SUBCUTANE.) to be added to the PDL as NONPREFERRED.

- The committee discussed the Antimigraine Agents, Triptans therapeutic class and recommended the following to the department by a unanimous vote:
    - SUMATRIPTAN (NASAL), SUMATRIPTAN KIT (SUBCUTANE.), SUMATRIPTAN DISP SYRINGE (SUBCUTANE.) and SUMATRIPTAN VIAL (SUBCUTANE.) to be moved on the PDL to PREFERRED.
    - SYMBRAVO TABLET (ORAL) to be added to the PDL as NONPREFERRED.
    - IMITREX KIT (SUBCUTANE.) and ZOMIG (NASAL) to be moved on the PDL to NONPREFERRED.
    - IMITREX VIAL (SUBCUTANE.) to be removed from the PDL.

- The committee discussed the Antipsychotics therapeutic class and recommended the following to the department by a unanimous vote:
    - ZIPRASIDONE (INTRAMUSC) to be moved on the PDL to PREFERRED.
    - BYSANTI (ORAL) to be to be added to the PDL as NONPREFERRED.

- The committee discussed the Cytokine and CAM Antagonists therapeutic class and recommended the following to the department by a unanimous vote:

- STARJEMZA SYRINGE (SUBCUTANE.), STARJEMZA VIAL (SUBCUTANE.), TOFACITINIB (ORAL), TOFACITINIB ER (ORAL), TYENNE VIAL (INTRAVENOUS), TYENNE PEN (SUBCUTANE.) and TYENNE SYRINGE (SUBCUTANE.) to be added to the PDL as PREFERRED.
- TYENNE VIAL (INTRAVENOUS), TYENNE PEN (SUBCUTANE.) and TYENNE SYRINGE (SUBCUTANE.) to be moved on the PDL to PREFERRED.
- ICOTYDE (ORAL), STARJEMZA VIAL (INTRAVENOUS) and USTEKINUMAB -AAUZ SYRINGE (SUBCUTANE.) (INTRAVENOUS) to be added to the PDL as NONPREFERRED.
- PYZCHIVA VIAL (SUBCUTANE.), PYZCHIVA SYRINGE (SUBCUTANEOUS), PYZCHIVA VIAL (INTRAVENOUS), STEQEYMA SYRINGE (SUBCUTANE.), STEQEYMA VIAL (INTRAVENOUS), XELJANZ (ORAL), YESINTEK SYRINGE (SUBCUTANE.), YESINTEK VIAL (SUBCUTANE.) to be moved on the PDL to NONPREFERRED.

- The committee discussed the Hypoglycemics, Incretin Mimetics/Enhancers therapeutic class and recommended the following to the department by a unanimous vote:
  - MOUNJARO (SUBCUTANE.) to be moved on the PDL to PREFERRED.
  - OZEMPIC TABLET (ORAL) to be added to the PDL as PREFERRED.
  - JANUMET XR (ORAL) to be moved on the PDL to NONPREFERRED.
  - DAPAGLIFLOZIN/SAXAGLIPTIN (ORAL), LINAGLIPTIN/METFORMIN (ORAL), SITAGLIPTIN/METFORMIN ER (ORAL) (ZITUVIMET XR), SITAGLIPTIN PHOSPHATE (ORAL) and SITAGLIPTIN PHOS/METFORMIN (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Immunomodulators, Asthma therapeutic class and recommended the following to the department by a unanimous vote:
  - NUCALA AUTO-INJECTOR (SUBCUTANEOUS), NUCALA SYRINGE (SUBCUTANEOUS) and NUCALA VIAL (SUBCUTANEOUS) to be moved on the PDL to PREFERRED.
  - EXDENSUR SYRINGE (SUBCUTANEOUS) to be added to the PDL as NONPREFERRED.

- The committee discussed the NSAIDs therapeutic class and recommended the following to the department by a unanimous vote:
  - DICLOFENAC POTASSIUM TABLET (ORAL) to be moved on the PDL to PREFERRED.
  - COXANTO (ORAL), DOLOBID (ORAL), ORUDIS (ORAL), VYSCOXA SUSPENSION (ORAL) and ZYBIC ORAL SUSP (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Stimulants and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - VYVANSE CAPSULE (ORAL) to be moved on the PDL to NONPREFERRED.
  - ARYNTA SOLUTION (ORAL) and LISDEXAMFETAMINE CHEWABLE TABLET (ORAL) to be added to the PDL as NONPREFERRED.

CONSENT AGENDA ITEMS:
The committee discussed and recommended by unanimous vote that all classes under the Consent Agenda Items be approved as presented.

Other Business

- DHS acknowledged and expressed appreciation to all who made the time to attend the meeting and provide testimony.
- DFC members were encouraged to consider running for the position of Chair of the Committee.
- DHS shared that there are a number of vacancies on the DFC that still need to be filled.

Adjournment

- The meeting was adjourned at approximately 12:52 pm Central Time.